Theravance Biopharma (TBPH)
NASDAQ:TBPH
Want to see TBPH full AI Analyst Report?
TBPH Stock Chart & Stats
$17.23
-$0.06(-0.65%)
At close: 4:00 PM EST
$17.23
-$0.06(-0.65%)
Day’s Range― - ―
52-Week Range$10.44 - $21.03
Previous CloseN/A
Volume28.33K
Average Volume (3M)387.94K
Market Cap
$908.88M
Enterprise Value$646.65M
Total Cash (Recent Filing)$394.67M
Total Debt (Recent Filing)$73.30M
Price to Earnings (P/E)7.8
Beta1.07
Next Earnings
Aug 05, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.26
Shares Outstanding51,553,005
10 Day Avg. Volume372,736
30 Day Avg. Volume387,936
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)3.17
Price to Sales (P/S)8.76
P/FCF Ratio3.95
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue5.89
Enterprise Value/Gross Profit7.33
Enterprise Value/Ebitda4.54
Forecast
1Y Price Target
$18.00Price Target Upside4.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)2.35
Revenue Forecast (FY)$103.44M
Bulls Say, Bears Say
Bulls Say
Strong Operating And Free Cash FlowTheravance’s marked shift to very large positive operating and free cash flow in 2025 and TTM provides durable internal funding for R&D, commercialization and debt servicing. Sustainable cash generation improves capital allocation flexibility and reduces reliance on external financing for strategic initiatives.
YUPELRI Patent Settlement Through 2039The settlement that defines a generic entry date in 2039 materially extends the branded YUPELRI exclusivity window, giving long-term revenue visibility. This structural protection supports multi-year cash flow planning, commercialization ROI and lowers near-term generic erosion risk for the core product.
Improved Balance Sheet And Low LeverageLow debt and a recovered, positive equity base provide balance-sheet flexibility to fund growth, weather setbacks, and pursue partnerships or opportunistic investments. Reduced leverage also lowers financial risk and interest sensitivity, strengthening long-term solvency prospects.
Bears Say
Core Operating Profitability Still Negative (EBIT)Despite improvements in cash flow and EBITDA, persistent negative EBIT indicates core operations have not yet achieved consistent operating profitability. This suggests ongoing structural cost or revenue mix issues that could limit sustainable margin expansion and long-term free cash flow durability.
Earnings Quality Influenced By Non-operating ItemsNet income exceeding revenue implies material non-operating or one-time gains underpin reported profitability. That raises questions about durability of earnings, makes forecasting core performance harder, and risks misstating the company's true operational cash-generating capacity over time.
Historical Volatility In Cash Flow And EquityRecent strong results follow multi-year volatility: cash flow was negative in 2022–2024 and equity was negative in 2021. This episodic performance history suggests execution and cyclic risks remain, complicating long-term planning and increasing the risk that strong recent cash generation may not be fully persistent.
Theravance Biopharma News
TBPH FAQ
What was Theravance Biopharma’s price range in the past 12 months?
Theravance Biopharma lowest stock price was $10.44 and its highest was $21.03 in the past 12 months.
What is Theravance Biopharma’s market cap?
Theravance Biopharma’s market cap is $908.88M.
When is Theravance Biopharma’s upcoming earnings report date?
Theravance Biopharma’s upcoming earnings report date is Aug 05, 2026 which is in 38 days.
How were Theravance Biopharma’s earnings last quarter?
Theravance Biopharma released its earnings results on May 07, 2026. The company reported -$0.1 earnings per share for the quarter, missing the consensus estimate of $0.028 by -$0.128.
Is Theravance Biopharma overvalued?
According to Wall Street analysts Theravance Biopharma’s price is currently Undervalued.
Does Theravance Biopharma pay dividends?
Theravance Biopharma does not currently pay dividends.
What is Theravance Biopharma’s EPS estimate?
Theravance Biopharma’s EPS estimate is 0.06.
How many shares outstanding does Theravance Biopharma have?
Theravance Biopharma has 51,553,005 shares outstanding.
What happened to Theravance Biopharma’s price movement after its last earnings report?
Theravance Biopharma reported an EPS of -$0.1 in its last earnings report, missing expectations of $0.028. Following the earnings report the stock price went up 0.472%.
Which hedge fund is a major shareholder of Theravance Biopharma?
Currently, no hedge funds are holding shares in TBPH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Theravance Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (4.47% Upside)
$18.00 (4.47% Upside)
Blogger Sentiment
Bullish
TBPH Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 35.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 24.2%
Last 30 Days ▲ 15.1%
Last 30 Days ▲ 15.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
64.30%
12-Months-Change
Fundamentals
Return on Equity
43.85%
Trailing 12-Months
Asset Growth
37.47%
Trailing 12-Months
Company Description
Theravance Biopharma
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
TBPH Stock 12 Month Forecast
Average Price Target
$18.00
▲(4.47% Upside)
Technical Analysis
Ownership Overview
6.40% Insiders
10.01% Mutual Funds
53.96% Other Institutional Investors
17.20% Public Companies and
Individual Investors